Research Challenges Claims Against Tylenol Use in Pregnancy
“Avoid Tylenol at all costs. Seriously, fight the urge to take it.” This strong guidance came from President Donald Trump during a September announcement with Health Secretary Robert F. Kennedy, Jr., where they warned that pregnant women should steer clear of Tylenol, citing a supposed connection to autism.
It’s worth noting that at the time of Trump’s remarks, there was no solid scientific backing to support this claim. Recently, researchers have conducted perhaps the most comprehensive review of the literature on this topic.
Their findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, showed no evidence linking acetaminophen, the main ingredient in Tylenol, to autism, ADHD, or intellectual disabilities when taken during pregnancy.
The authors aimed to clarify misconceptions following Trump’s statements, emphasizing that leaving a fever untreated can endanger both mother and child.
“After these comments, many moms became anxious about taking paracetamol,” noted Dr. Francesco D’Antonio, a lead author from the University of Chieti in Italy. “We saw a significant spike in inquiries from women the very next day.”
The main conclusion of the report? Acetaminophen is considered safe during pregnancy. Dr. Asma Khalil, another co-author and consultant obstetrician at St. George’s Hospital in London, affirmed, “It’s still the first-line treatment we recommend for pain or fever in pregnant women.”
The Lancet described this work as a “gold-standard evidence review,” a phrase that resonates with claims from the Trump administration about upcoming unbiased scientific investigations into autism’s origins.
Four independent researchers praised the thoroughness of the analysis. David Mandell, a psychiatry professor at the University of Pennsylvania, remarked, “I can’t think of a more effective way to analyze the data than this Lancet paper.”
The team, comprised of researchers from the U.K., Italy, and Sweden, employed three distinct methods to assess studies up until September.
First off, they excluded studies that didn’t compare situations where Tylenol was used against those where it wasn’t, along with studies lacking details on the health history of the mothers or the medications taken. Additionally, they avoided studies relying on self-reporting about Tylenol usage and autism. Ultimately, they ended up carefully reviewing 43 relevant studies.
Following this, they scored these studies on their quality and checked for any biases. They discarded lower-quality studies, especially those that didn’t consistently follow participants or lacked clear outcome definitions.
Lastly, they conducted an in-depth evaluation of the two most rigorous studies which analyzed Tylenol use and autism among siblings—one set exposed to Tylenol in utero and the other not. This method helped control for genetic and environmental factors, making the findings more reliable.
Across all three analysis methods, the conclusion remained steadfast: no association between Tylenol use during pregnancy and developmental disorders was found.
In response to these findings, an official from the Health and Human Services Department stated that this analysis doesn’t settle the debate on a potential connection between Tylenol and autism. They suggested the study might have engineered results by excluding varying evidence and creating a biased design.
The spokesperson, Andrew Nixon, cited concerns from experts regarding acetaminophen during pregnancy, specifically mentioning Dr. Andrea Baccarelli from Harvard T.H. Chan School of Public Health. Baccarelli’s previous review suggested a link between autism and Tylenol use, a point the Trump administration had used to bolster its claims. However, Baccarelli did not respond to requests for comments.
Khalil argued that Baccarelli’s review, along with other smaller studies, likely didn’t adequately rule out confounding variables.
Mandell added that Baccarelli’s review didn’t evaluate nearly as many articles as their new assessment did, suggesting a lack of thoroughness.
“It really points to a hasty search,” he commented.
Since his initial remarks, Trump has reiterated his stance, stating, “Pregnant women, avoid Tylenol unless it’s absolutely necessary.”
Yet, a warning issued by the FDA alongside the September announcement simply encouraged consideration for minimizing acetaminophen use while still labeling it as the safest over-the-counter option for managing pain and fever during pregnancy, noting that the suspected link to autism remains “an ongoing area of scientific debate.”
Experts in autism research believe there’s no need for ongoing discussion about this issue.
